<p>Terns Pharmaceuticals（纳斯达克代码：TERN - 获取免费报告）在周四发布的研究报告中，投资分析师 Citizens Jmp 将其目标价从 35.00 美元上调至 57.00 美元，Benzinga 报道。该公司目前对该股票的评级为 “市场表现优于大盘”。Citizens Jmp 的目标价暗示该公司股价有 27.77% 的上涨潜力。</p>
<p>获取 <strong>Terns Pharmaceuticals</strong> 的提醒：</p>
<p>其他几家券商最近也对 TERN 发表了评论。Truist Financial 在周二将 Terns Pharmaceuticals 的目标价从 35.00 美元上调至 56.00 美元，并给予该股票 “买入” 评级。瑞穗证券在周二将 Terns Pharmaceuticals 的目标价从 33.00 美元上调至 54.00 美元，并给予该股票 “表现优于大盘” 评级。HC Wainwright 在周二将 Terns Pharmaceuticals 的目标价从 20.00 美元上调至 60.00 美元，并给予该公司 “买入” 评级。巴克莱在周二将 Terns Pharmaceuticals 的目标价从 36.00 美元上调至 56.00 美元，并给予该股票 “超配” 评级。最后，William Blair 在 11 月 3 日的研究报告中将 Terns Pharmaceuticals 的评级从 “市场表现” 上调至 “表现优于大盘”。一位投资分析师给予该股票 “强烈买入” 评级，十一位给予 “买入” 评级，一位给予 “卖出” 评级。根据 MarketBeat.com 的数据，Terns Pharmaceuticals 的平均评级为 “适度买入”，平均目标价为 55.56 美元。</p>
<p><strong>查看我们关于 TERN 的最新报告</strong></p>
<h2>Terns Pharmaceuticals 价格表现</h2>
<p>纳斯达克 TERN 在周四开盘价为 44.61 美元。该公司的 50 日移动平均价格为 18.21 美元，200 日移动平均价格为 10.03 美元。该股票的市值为 40.2 亿美元，市盈率为-43.31，贝塔值为-0.24。Terns Pharmaceuticals 的 52 周低点为 1.87 美元，52 周高点为 48.26 美元。</p>
<p>Terns Pharmaceuticals（纳斯达克代码：TERN - 获取免费报告）在 11 月 10 日星期一最后发布了季度财报。该公司报告每股收益（EPS）为-0.27 美元，超出市场共识预期的-0.30 美元，超出幅度为 0.03 美元。整体来看，卖方分析师预计 Terns Pharmaceuticals 在本年度的每股收益将为-1.19 美元。</p>
<h2>Terns Pharmaceuticals 的内部交易</h2>
<p>在其他 Terns Pharmaceuticals 的新闻中，董事 Jill M. Quigley 在 11 月 4 日星期二出售了 24,520 股该公司的股票。该股票以平均价格 18.00 美元出售，总交易额为 441,360.00 美元。此次出售已在向证券交易委员会提交的文件中披露，相关文件可通过此链接访问。公司内部人士持有该公司 1.50% 的股份。</p>
<h2>机构资金流入和流出</h2>
<p>几家对冲基金最近调整了对该股票的持有。工程师门控管理 LP 在第二季度购买了 Terns Pharmaceuticals 的新股份，价值 41,000 美元。加拿大养老金计划投资委员会在第二季度购买了 Terns Pharmaceuticals 的新头寸，价值 46,000 美元。LeConte Wealth Management LLC 在第二季度购买了 Terns Pharmaceuticals 的新头寸，价值 47,000 美元。Dynamic Technology Lab Private Ltd 在第一季度购买了 Terns Pharmaceuticals 的新股份，价值 51,000 美元。最后，Velan Capital Investment Management LP 在第二季度将其在 Terns Pharmaceuticals 的股份增加了 17.6%。Velan Capital Investment Management LP 目前持有该公司 20,000 股股票，价值 75,000 美元，此前在上个季度又增持了 3,000 股。对冲基金和其他机构投资者持有该公司 98.26% 的股份。</p>
<h2>关于 Terns Pharmaceuticals</h2>
<p>（获取免费报告）</p>
<p>Terns Pharmaceuticals, Inc 是一家临床阶段的生物制药公司，开发用于治疗肿瘤、代谢功能障碍相关性脂肪肝炎（MASH）和肥胖的小分子产品候选药物。该公司正在开发 TERN-701，这是一种别构 BCR-ABL 酪氨酸激酶抑制剂（TKI），目前正在进行慢性髓性白血病（CML）的第一阶段临床试验，这是一种起源于骨髓的癌症。</p>
<h2>进一步阅读</h2>
<ul>
<li>我们更看好的五只股票，胜过 Terns Pharmaceuticals</li>
<li>如何开始投资房地产</li>
<li>沃尔玛的纳斯达克切换可能会改变 WMT 股票的一切</li>
<li>便士股票是否适合你的投资组合？</li>
<li>GameStop 看起来崩溃：为什么 GME 可能在 2026 年崩盘</li>
<li>REIT 股票 - 今天值得加入你投资组合的最佳 REIT 股票</li>
<li>市场动量：3 只有望大幅突破的股票</li>
</ul>
<p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/RatingsAndPriceTargetChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9VEVSTg?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/RatingsAndPriceTargetChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9VEVSTg"/></p>
<p><em>此即时新闻提醒由叙述科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快的报道和公正的覆盖。请将任何问题或意见发送至 contact@marketbeat.com。</em></p>
<h2>你现在应该投资 1,000 美元在 Terns Pharmaceuticals 吗？</h2>
<p>在你考虑 Terns Pharmaceuticals 之前，你需要听听这个。</p>
<p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已识别出五只顶级分析师正在悄悄向客户推荐的股票，以便在更广泛的市场注意到之前购买……而 Terns Pharmaceuticals 并不在名单上。</p>
<p>虽然 Terns Pharmaceuticals 目前在分析师中获得 “适度买入” 评级，但顶级分析师认为这五只股票更值得购买。</p>
<p>查看这五只股票</p>

TERN

<p>Citizens Jmp 将 Terns Pharmaceuticals 的目标股价从 35.00 美元上调至 57.00 美元，给予其 “市场表现优于大盘” 的评级。其他公司也提高了他们的目标价，Truist Financial、Mizuho、HC Wainwright 和 Barclays 都上调了他们的价格目标。该股票周四以 44.61 美元开盘，市值为 40.2 亿美元。分析师预计 Terns Pharmaceuticals 本年度每股收益为 -1.19 美元。机构投资者持有该股票的 98.26%</p>

<p>Terns Pharmaceuticals (NASDAQ:TERN - Get Free Report) had its price target boosted by investment analysts at Citizens Jmp from $35.00 to $57.00 in a research report issued on Thursday,Benzinga reports. The firm presently has a &#34;market outperform&#34; rating on the stock. Citizens Jmp's price target suggests a potential upside of 27.77% from the company's previous close.</p>
<div class="lb-trans"><p>Terns Pharmaceuticals（纳斯达克代码：TERN - 获取免费报告）在周四发布的研究报告中，投资分析师 Citizens Jmp 将其目标价从 35.00 美元上调至 57.00 美元，Benzinga 报道。该公司目前对该股票的评级为 “市场表现优于大盘”。Citizens Jmp 的目标价暗示该公司股价有 27.77% 的上涨潜力。</p>
</div><p>Get <strong>Terns Pharmaceuticals</strong> alerts:</p>
<div class="lb-trans"><p>获取 <strong>Terns Pharmaceuticals</strong> 的提醒：</p>
</div><p>Several other brokerages also recently commented on TERN. Truist Financial boosted their target price on Terns Pharmaceuticals from $35.00 to $56.00 and gave the stock a &#34;buy&#34; rating in a research note on Tuesday. Mizuho upped their price objective on shares of Terns Pharmaceuticals from $33.00 to $54.00 and gave the stock an &#34;outperform&#34; rating in a research report on Tuesday. HC Wainwright raised their target price on shares of Terns Pharmaceuticals from $20.00 to $60.00 and gave the company a &#34;buy&#34; rating in a research report on Tuesday. Barclays boosted their target price on shares of Terns Pharmaceuticals from $36.00 to $56.00 and gave the stock an &#34;overweight&#34; rating in a research note on Tuesday. Finally, William Blair upgraded Terns Pharmaceuticals from a &#34;market perform&#34; rating to an &#34;outperform&#34; rating in a research report on Monday, November 3rd. One investment analyst has rated the stock with a Strong Buy rating, eleven have given a Buy rating and one has assigned a Sell rating to the company. Based on data from MarketBeat.com, Terns Pharmaceuticals has an average rating of &#34;Moderate Buy&#34; and an average target price of $55.56.</p>
<div class="lb-trans"><p>其他几家券商最近也对 TERN 发表了评论。Truist Financial 在周二将 Terns Pharmaceuticals 的目标价从 35.00 美元上调至 56.00 美元，并给予该股票 “买入” 评级。瑞穗证券在周二将 Terns Pharmaceuticals 的目标价从 33.00 美元上调至 54.00 美元，并给予该股票 “表现优于大盘” 评级。HC Wainwright 在周二将 Terns Pharmaceuticals 的目标价从 20.00 美元上调至 60.00 美元，并给予该公司 “买入” 评级。巴克莱在周二将 Terns Pharmaceuticals 的目标价从 36.00 美元上调至 56.00 美元，并给予该股票 “超配” 评级。最后，William Blair 在 11 月 3 日的研究报告中将 Terns Pharmaceuticals 的评级从 “市场表现” 上调至 “表现优于大盘”。一位投资分析师给予该股票 “强烈买入” 评级，十一位给予 “买入” 评级，一位给予 “卖出” 评级。根据 MarketBeat.com 的数据，Terns Pharmaceuticals 的平均评级为 “适度买入”，平均目标价为 55.56 美元。</p>
</div><p><strong>View Our Latest Report on TERN</strong></p>
<div class="lb-trans"><p><strong>查看我们关于 TERN 的最新报告</strong></p>
</div><h2>Terns Pharmaceuticals Price Performance</h2>
<div class="lb-trans"><h2>Terns Pharmaceuticals 价格表现</h2>
</div><p>NASDAQ TERN opened at $44.61 on Thursday. The business has a fifty day moving average price of $18.21 and a two-hundred day moving average price of $10.03. The stock has a market capitalization of $4.02 billion, a PE ratio of -43.31 and a beta of -0.24. Terns Pharmaceuticals has a fifty-two week low of $1.87 and a fifty-two week high of $48.26.</p>
<div class="lb-trans"><p>纳斯达克 TERN 在周四开盘价为 44.61 美元。该公司的 50 日移动平均价格为 18.21 美元，200 日移动平均价格为 10.03 美元。该股票的市值为 40.2 亿美元，市盈率为-43.31，贝塔值为-0.24。Terns Pharmaceuticals 的 52 周低点为 1.87 美元，52 周高点为 48.26 美元。</p>
</div><p>Terns Pharmaceuticals (NASDAQ:TERN - Get Free Report) last issued its quarterly earnings results on Monday, November 10th. The company reported ($0.27) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.30) by $0.03. As a group, sell-side analysts expect that Terns Pharmaceuticals will post -1.19 earnings per share for the current year.</p>
<div class="lb-trans"><p>Terns Pharmaceuticals（纳斯达克代码：TERN - 获取免费报告）在 11 月 10 日星期一最后发布了季度财报。该公司报告每股收益（EPS）为-0.27 美元，超出市场共识预期的-0.30 美元，超出幅度为 0.03 美元。整体来看，卖方分析师预计 Terns Pharmaceuticals 在本年度的每股收益将为-1.19 美元。</p>
</div><h2>Insider Transactions at Terns Pharmaceuticals</h2>
<div class="lb-trans"><h2>Terns Pharmaceuticals 的内部交易</h2>
</div><p>In other Terns Pharmaceuticals news, Director Jill M. Quigley sold 24,520 shares of the business's stock in a transaction that occurred on Tuesday, November 4th. The stock was sold at an average price of $18.00, for a total transaction of $441,360.00. The sale was disclosed in a document filed with the Securities &amp; Exchange Commission, which can be accessed through this link. Company insiders own 1.50% of the company's stock.</p>
<div class="lb-trans"><p>在其他 Terns Pharmaceuticals 的新闻中，董事 Jill M. Quigley 在 11 月 4 日星期二出售了 24,520 股该公司的股票。该股票以平均价格 18.00 美元出售，总交易额为 441,360.00 美元。此次出售已在向证券交易委员会提交的文件中披露，相关文件可通过此链接访问。公司内部人士持有该公司 1.50% 的股份。</p>
</div><h2>Institutional Inflows and Outflows</h2>
<div class="lb-trans"><h2>机构资金流入和流出</h2>
</div><p>Several hedge funds have recently modified their holdings of the stock. Engineers Gate Manager LP bought a new stake in Terns Pharmaceuticals during the second quarter worth $41,000. Canada Pension Plan Investment Board bought a new position in Terns Pharmaceuticals during the 2nd quarter valued at $46,000. LeConte Wealth Management LLC purchased a new position in Terns Pharmaceuticals during the 2nd quarter worth $47,000. Dynamic Technology Lab Private Ltd bought a new stake in shares of Terns Pharmaceuticals in the 1st quarter worth $51,000. Finally, Velan Capital Investment Management LP grew its stake in shares of Terns Pharmaceuticals by 17.6% in the 2nd quarter. Velan Capital Investment Management LP now owns 20,000 shares of the company's stock worth $75,000 after acquiring an additional 3,000 shares in the last quarter. Hedge funds and other institutional investors own 98.26% of the company's stock.</p>
<div class="lb-trans"><p>几家对冲基金最近调整了对该股票的持有。工程师门控管理 LP 在第二季度购买了 Terns Pharmaceuticals 的新股份，价值 41,000 美元。加拿大养老金计划投资委员会在第二季度购买了 Terns Pharmaceuticals 的新头寸，价值 46,000 美元。LeConte Wealth Management LLC 在第二季度购买了 Terns Pharmaceuticals 的新头寸，价值 47,000 美元。Dynamic Technology Lab Private Ltd 在第一季度购买了 Terns Pharmaceuticals 的新股份，价值 51,000 美元。最后，Velan Capital Investment Management LP 在第二季度将其在 Terns Pharmaceuticals 的股份增加了 17.6%。Velan Capital Investment Management LP 目前持有该公司 20,000 股股票，价值 75,000 美元，此前在上个季度又增持了 3,000 股。对冲基金和其他机构投资者持有该公司 98.26% 的股份。</p>
</div><h2>About Terns Pharmaceuticals</h2>
<div class="lb-trans"><h2>关于 Terns Pharmaceuticals</h2>
</div><p>(Get Free Report)</p>
<div class="lb-trans"><p>（获取免费报告）</p>
</div><p>Terns Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, develops small-molecule product candidates for the treatment of oncology, metabolic dysfunction-associated steatohepatitis (MASH), and obesity. The company develops TERN-701, an allosteric BCR-ABL tyrosine kinase inhibitor (TKI) that is in phase 1 clinical trial for chronic myeloid leukemia (CML), a form of cancer that starts in bone marrow.</p>
<div class="lb-trans"><p>Terns Pharmaceuticals, Inc 是一家临床阶段的生物制药公司，开发用于治疗肿瘤、代谢功能障碍相关性脂肪肝炎（MASH）和肥胖的小分子产品候选药物。该公司正在开发 TERN-701，这是一种别构 BCR-ABL 酪氨酸激酶抑制剂（TKI），目前正在进行慢性髓性白血病（CML）的第一阶段临床试验，这是一种起源于骨髓的癌症。</p>
</div><h2>Further Reading</h2>
<div class="lb-trans"><h2>进一步阅读</h2>
</div><ul>
<li>Five stocks we like better than Terns Pharmaceuticals</li>
<li>How to Start Investing in Real Estate</li>
<li>Walmart’s NASDAQ Switch Could Change Everything for WMT Stock</li>
<li>Are Penny Stocks a Good Fit for Your Portfolio?</li>
<li>GameStop Looks Broken: Here’s Why GME Could Crash in 2026</li>
<li>REIT Stocks - Best REIT Stocks to Add to Your Portfolio Today</li>
<li>Market Momentum: 3 Stocks Poised for Major Breakouts</li>
</ul>
<div class="lb-trans"><ul>
<li>我们更看好的五只股票，胜过 Terns Pharmaceuticals</li>
<li>如何开始投资房地产</li>
<li>沃尔玛的纳斯达克切换可能会改变 WMT 股票的一切</li>
<li>便士股票是否适合你的投资组合？</li>
<li>GameStop 看起来崩溃：为什么 GME 可能在 2026 年崩盘</li>
<li>REIT 股票 - 今天值得加入你投资组合的最佳 REIT 股票</li>
<li>市场动量：3 只有望大幅突破的股票</li>
</ul>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/RatingsAndPriceTargetChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9VEVSTg" alt="" original-src="https://www.marketbeat.com/scripts/RatingsAndPriceTargetChart.ashx?Prefix=NASDAQ&amp;Symbol=TERN"/></p>
<p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即时新闻提醒由叙述科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快的报道和公正的覆盖。请将任何问题或意见发送至 contact@marketbeat.com。</em></p>
</div><h2>Should You Invest $1,000 in Terns Pharmaceuticals Right Now?</h2>
<div class="lb-trans"><h2>你现在应该投资 1,000 美元在 Terns Pharmaceuticals 吗？</h2>
</div><p>Before you consider Terns Pharmaceuticals, you'll want to hear this.</p>
<div class="lb-trans"><p>在你考虑 Terns Pharmaceuticals 之前，你需要听听这个。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Terns Pharmaceuticals wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已识别出五只顶级分析师正在悄悄向客户推荐的股票，以便在更广泛的市场注意到之前购买……而 Terns Pharmaceuticals 并不在名单上。</p>
</div><p>While Terns Pharmaceuticals currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>虽然 Terns Pharmaceuticals 目前在分析师中获得 “适度买入” 评级，但顶级分析师认为这五只股票更值得购买。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>查看这五只股票</p>
</div>

Terns Pharmaceuticals（纳斯达克代码：TERN）的目标股价被上调至 57.00 美元